Literature DB >> 8697388

Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study.

G B Kristensen1, R Holm, V M Abeler, C G Tropé.   

Abstract

BACKGROUND: This study evaluated the prognostic significance of immunohistochemical staining for cathepsin D, epidermal growth factor receptor (EGFR), and c-erbB-2 in patients with early cervical squamous cell carcinoma.
METHODS: This retrospective analysis comprised 132 patients, all subjected to radical hysterectomy with bilateral pelvic lymphadenectomy for International Federation of Gynecology and Obstetrics (FIGO) Stage IB cervical squamous cell carcinoma. Immunohistochemical staining was correlated with various histopathologic and morphologic characteristics (i.e., tumor size, grade of differentiation, vessel invasion, invasion into parametria, and lymph node metastasis) and relapse free survival.
RESULTS: Positive staining for cathepsin D was observed in 47% of tumors, more frequent in tumors giving rise to lymph node metastases. The relapse free survival was lower for patients with cathepsin D positive tumors. Overexpression of EGFR was observed in 25.8% of the tumors. There was no correlation with any of the histopathologic variables investigated. Relapse free survival was lower for patients with tumors overexpressing EGFR. Immunohistochemical staining for c-erbB-2 was observed in 12.1% of tumors with no correlation with relapse free survival. In multivariate analysis, immunostaining of cathepsin D and EGFR obtained independent prognostic significance, and considered together (both negative, one positive, or both positive) was the strongest prognostic factor after tumor size.
CONCLUSIONS: Immunohistochemical staining for cathepsin D and EGFR is useful as a tool for evaluation of tumor aggressiveness in patients with early cervical squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697388     DOI: 10.1002/(SICI)1097-0142(19960801)78:3<433::AID-CNCR9>3.0.CO;2-K

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.

Authors:  John Farley; Michael W Sill; Michael Birrer; Joan Walker; Russell J Schilder; J Tate Thigpen; Robert L Coleman; Brigitte E Miller; Peter G Rose; Heather A Lankes
Journal:  Gynecol Oncol       Date:  2011-02-16       Impact factor: 5.482

2.  Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.

Authors:  Adhemar Longatto-Filho; Céline Pinheiro; Olga Martinho; Marise A R Moreira; Luiz F J Ribeiro; Geraldo S Queiroz; Fernando C Schmitt; Fátima Baltazar; Rui M Reis
Journal:  BMC Cancer       Date:  2009-06-29       Impact factor: 4.430

3.  Malignant tumours of the genital tract among Batswana women.

Authors:  M N Tanko; M A Kayembe; F Cainelli; S Vento
Journal:  Ghana Med J       Date:  2012-09

Review 4.  Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications.

Authors:  Gaetano Leto; Francesca M Tumminello; Marilena Crescimanno; Carla Flandina; Nicola Gebbia
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.

Authors:  K Iida; K Nakayama; M T Rahman; M Rahman; M Ishikawa; A Katagiri; S Yeasmin; Y Otsuki; H Kobayashi; S Nakayama; K Miyazaki
Journal:  Br J Cancer       Date:  2011-07-05       Impact factor: 7.640

6.  Anti-EGFR-Conjugated Hollow Gold Nanospheres Enhance Radiocytotoxic Targeting of Cervical Cancer at Megavoltage Radiation Energies.

Authors:  Jiao Liu; Ying Liang; Ting Liu; Dengke Li; Xingsheng Yang
Journal:  Nanoscale Res Lett       Date:  2015-05-15       Impact factor: 4.703

7.  Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis.

Authors:  Wei-Jie Tian; Miao-Ling Huang; Qing-Feng Qin; Qing Chen; Kun Fang; Ping-Ling Wang
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

8.  Loss of E-cadherin and Acquisition of Vimentin in Epithelial-Mesenchymal Transition are Noble Indicators of Uterine Cervix Cancer Progression.

Authors:  Na-Hye Myong
Journal:  Korean J Pathol       Date:  2012-08-23

9.  EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy.

Authors:  Li Shen; Yongjie Shui; Xiaojia Wang; Liming Sheng; Zhengyan Yang; Danfeng Xue; Qichun Wei
Journal:  BMC Cancer       Date:  2008-08-12       Impact factor: 4.430

10.  HER2 expression in cervical cancer as a potential therapeutic target.

Authors:  Alma Chavez-Blanco; Victor Perez-Sanchez; Aurora Gonzalez-Fierro; Teresa Vela-Chavez; Myrna Candelaria; Lucely Cetina; Silvia Vidal; Alfonso Dueñas-Gonzalez
Journal:  BMC Cancer       Date:  2004-09-01       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.